Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection
Six-week oral treatment can cure hard-to-treat hepatitis C patients
US medical societies launch new hepatitis C treatment guidelines
Low lymphocyte count a risk factor for infections for people taking HCV therapy
Gilead two-drug hep C combination cures 94% of genotype 1 patients in eight weeks
Ritonavir the cause of the interaction between telaprevir and ritonavir-boosted atazanavir
AbbVie reports 96% cure rate for interferon-free hepatitis C regimen in phase 3 study
Successful hepatitis C treatment reduces risk of liver cancer and death, but most remain untreated
